CymaBay Therapeutics Inc. (CBAY) News

CymaBay Therapeutics Inc. (CBAY): $3.89

0.09 (+2.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CBAY to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

Filter CBAY News Items

CBAY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CBAY News Highlights

  • For CBAY, its 30 day story count is now at 5.
  • Over the past 3 days, the trend for CBAY's stories per day has been choppy and unclear. It has oscillated between 1 and 4.

Latest CBAY News From Around the Web

Below are the latest news stories about CymaBay Therapeutics Inc that investors may wish to consider to help them evaluate CBAY as an investment opportunity.

A Look At The Fair Value Of CymaBay Therapeutics, Inc. (NASDAQ:CBAY)

Today we will run through one way of estimating the intrinsic value of CymaBay Therapeutics, Inc. ( NASDAQ:CBAY ) by...

Yahoo | September 2, 2021

CymaBay Therapeutics to Present at Upcoming Investor Conferences

NEWARK, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual investor conferences including Citis 16th Annual BioPharma Virtual Conference taking place September 8-10, 2021, the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021 and the 2021 Cantor Virtual Global Healthcare Conference taking place September 27-30, 2021.

Intrado Digital Media | August 30, 2021

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV ) Alkermes plc (NASDAQ: ALKS ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Gilead Sciences, Inc. (NASDAQ: GILD ) GlaxoSmithKline plc (NYSE: GSK ) ( announced FDA approval for label expansion for its Jemperli) Novo Nordisk A/S (NYSE: NVO ) Innoviva, Inc. (NASDAQ: INVA ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI ) Omega Therapeutics, Inc. (NASDAQ: OMGA ) (IPOed July 30) Pfizer, Inc. (NYSE: PFE ) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) ResMed Inc. (NYSE: RMD ) TScan Therapeutics, Inc. (NASDAQ: TCRX ) Virpax Pharmaceutical...

Benzinga | August 19, 2021

CymaBay Therapeutics Inc. (CBAY) Q2 2021 Earnings Call Transcript

CBAY earnings call for the period ending June 30, 2021.

The Motley Fool | August 12, 2021

CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update

Secured up to $100 million of additional development funding through a non-dilutive financing transaction with Abingworth Funds the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC), including the Phase 3 RESPONSE clinical trial Actively recruiting patients in two global, clinical studies evaluating seladelpar in PBC RESPONSE, a 52-week, randomized, placebo-controlled, Phase 3 registrational studyASSURE, an open-label, long-term study Conference call and webcast tod

Yahoo | August 12, 2021

CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021

NEWARK, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY ), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, August 12, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2021 and to provide a business update. Conference Call Details To access the live conference call, please dial Full story available on Benzinga.com

Benzinga | August 5, 2021

CymaBay Secures $100M Non-Dilutive Funding To Fund Seladelpar Development Program

CymaBay Therapeutics Inc (NASDAQ: CBAY ) has received $100 million in non-dilutive financing from Abingworth to fund the Phase 3 development program for seladelpar in primary biliary cholangitis (PBC). Under the terms of the transaction, CymaBay will receive up to $100 million of seladelpar development costs, of which $75 million will be received in three Full story available on Benzinga.com

Benzinga | August 2, 2021

CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth

Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC CymaBay retains full worldwide commercial rights to seladelpar NEWARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced a $100 million non-dilutive financing transaction with Abingworth to fund the Phase 3 development

Yahoo | August 2, 2021

Were Hedge Funds Right About CymaBay Therapeutics Inc (CBAY)?

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Yahoo | July 26, 2021

Glucose Dependent Insulinotropic Receptor Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Amgen Inc, Arena Pharmaceuticals Inc, CymaBay Therapeutics Inc, Dong-A

This report studies the Glucose Dependent Insulinotropic Receptor Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Glucose Dependent Insulinotropic Receptor market segmented []

Jumbo News | July 24, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7247 seconds.